Exchange: NASDAQ·Updated 04:38 AM EDT
ENLV logo

ENLV Enlivex Therapeutics Ltd

$1.33
$0.02
(1.48%)
Pre-Market
Prev Close $1.35
Mkt Cap$23.61M
Vol8,704.00

About ENLV

Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
51

Neutral Sentiment

How do you feel about ENLV?

Advertisement|Remove ads.